tradingkey.logo

tradingkey.logo
怜玢


HUTCHMED (China) Ltd

HCM
りォッチリストに远加
14.480USD
+0.810+5.93%
終倀 09-21 16:00ET
2.53B時䟡総額
26.85盎近12ヶ月PER

{index_name}に぀いお HUTCHMED (China) Ltd 䌁業名

HUTCHMED (China) Ltd is an investment holding company principally engaged in the manufacture and sale of pharmaceuticals. The Company operates its business through two segments. Oncology Immunology segment is engaged in the discovery, development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Among it, research and development (R&D) includes research and development activities covering drug discovery, development, manufacturing and regulatory functions, out-licensing of in-house developed drugs, as well as administrative activities to support research and development operations, marketed products comprises the invoiced sales, marketing, manufacture and distribution of drugs developed from research and development activities. Other Ventures segment is engaged in the other commercial businesses which include the sales, marketing, manufacture and distribution of other prescription drugs and healthcare products.

HUTCHMED (China) Ltd プロフィヌル


䌁業コヌドHCM
䌚瀟名HUTCHMED (China) Ltd
䞊堎日May 19, 2006
最高経営責任者「CEO」Cheng (Chig Fung)
埓業員数1811
蚌刞皮類Depository Receipt
決算期末May 19
本瀟所圚地48th Floor, Cheung Kong Center, 2 Queen's Road Central
郜垂
蚌刞取匕所NASDAQ OMX - NASDAQ BASIC
囜Hong Kong
郵䟿番号- -
電話番号85221281188
りェブサむトhttps://www.hutch-med.com/
䌁業コヌドHCM
䞊堎日May 19, 2006
最高経営責任者「CEO」Cheng (Chig Fung)

HUTCHMED (China) Ltdの経営陣


䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Dr. Renu Bhatia
Dr. Renu Bhatia
Senior Lead Independent Non-Executive Director
Senior Lead Independent Non-Executive Director
16.00K
--
Ms. Edith Shih
Ms. Edith Shih
Non-Executive Director, Company Secretary
Non-Executive Director, Company Secretary
--
--
Mr. Chig Fung (Johnny) Cheng
Mr. Chig Fung (Johnny) Cheng
Acting Chief Executive Officer, Chief Financial Officer, Executive Director
Acting Chief Executive Officer, Chief Financial Officer, Executive Director
--
--
Dr. Dan Eldar, Ph.D.
Dr. Dan Eldar, Ph.D.
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
--
--
Dr. Weiguo Su, Ph.D.
Dr. Weiguo Su, Ph.D.
Chief Scientific Officer, Executive Director
Chief Scientific Officer, Executive Director
--
--
Prof. Shu Kam (Tony) Mok
Prof. Shu Kam (Tony) Mok
Senior Lead Non-Executive Independent Director
Senior Lead Non-Executive Independent Director
--
--
Dr. Qingmei (May) Wang, Ph.D.
Dr. Qingmei (May) Wang, Ph.D.
Senior Vice President - Business Development and Strategic Alliances
Senior Vice President - Business Development and Strategic Alliances
--
--
Dr. Zhenping Wu, Ph.D.
Dr. Zhenping Wu, Ph.D.
Executive Vice President - Pharmaceutical Sciences and Manufacturing
Executive Vice President - Pharmaceutical Sciences and Manufacturing
--
--
Mr. Kin Hung (Mark) Lee
Mr. Kin Hung (Mark) Lee
Senior Vice President - Corporate Management and Communications
Senior Vice President - Corporate Management and Communications
--
--
Mr. Charles George Rupert Nixon
Mr. Charles George Rupert Nixon
Group General Counsel
Group General Counsel
--
--
詳现を芋る
䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Dr. Renu Bhatia
Dr. Renu Bhatia
Senior Lead Independent Non-Executive Director
Senior Lead Independent Non-Executive Director
16.00K
--
Ms. Edith Shih
Ms. Edith Shih
Non-Executive Director, Company Secretary
Non-Executive Director, Company Secretary
--
--
Mr. Chig Fung (Johnny) Cheng
Mr. Chig Fung (Johnny) Cheng
Acting Chief Executive Officer, Chief Financial Officer, Executive Director
Acting Chief Executive Officer, Chief Financial Officer, Executive Director
--
--
Dr. Dan Eldar, Ph.D.
Dr. Dan Eldar, Ph.D.
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
--
--
Dr. Weiguo Su, Ph.D.
Dr. Weiguo Su, Ph.D.
Chief Scientific Officer, Executive Director
Chief Scientific Officer, Executive Director
--
--
Prof. Shu Kam (Tony) Mok
Prof. Shu Kam (Tony) Mok
Senior Lead Non-Executive Independent Director
Senior Lead Non-Executive Independent Director
--
--

よくある質問

HUTCHMED (China) Ltdの䞊䜍5名の株䞻は誰ですか


HUTCHMED (China) Ltdの䞊䜍5名の株䞻は以䞋のずおりです。Dr. Renu Bhatia

HUTCHMED (China) LtdHCMの株匏を保有しおいる機関の数はいく぀ですか


2026Q1時点で、HUTCHMED (China) Ltdの株匏を保有しおいる機関は139瀟あり、保有株匏の総垂堎䟡倀は玄5.33Mで、党䜓の3.05%を占めおいたす。2025Q4ず比范しお、機関の持ち株は-5943889.00増加しおいたす。
tradingkey.logo
リスク告知圓瀟りェブサむト及びモバむルアプリは特定の投資商品に関する䞀般的な情報のみを提䟛しおおり、Finsightsは金融アドバむスや投資商品の掚奚を行うものではありたせん。本情報の提䟛をもっおFinsightsが投資助蚀を行っおいるず解釈されるこずはありたせん。
投資商品には元本割れを含む重倧なリスクが䌎い、党おの投資家に適するものではありたせん。なお、過去の運甚実瞟は将来の成果を保蚌するものではありたせん。
Finsightsは、第䞉者広告䞻たたは提携先が圓瀟りェブサむト・モバむルアプリ䞊に広告を掲茉するこずを蚱可する堎合があり、これら広告䞻から広告ぞの反応に基づく報酬を受けるこずがありたす。
© 著䜜暩: FINSIGHTS MEDIA PTE. LTD. 無断耇写・転茉を犁じたす。